What Makes Remibrutinib a Game-Changer in Chronic Spontaneous Urticaria Therapy?
Remibrutinib represents a specialized Bruton's tyrosine kinase (BTK) inhibitor under investigation by Novartis for potential use in treating chronic spontaneous urticaria (CSU).
How to Choose a Quality CDMO Partner?
To survive in the tough and competitive world of pharma development, a company needs to have the right CDMO. With a time frame of years in drug development, every step from discovery to market is not an easy one.
CRO, CMO and CDMO: Understanding the Key Differences
In pharmaceutical and biotech circles, the acronyms CRO, CMO, and CDMO stand for three distinct but interrelated entities. The pharmaceutical sector depends on outsource partners to automate the drug development and manufacturing process.
